Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain

Research output: Contribution to journalReviewResearchpeer-review

Standard

Pain and Nociception : Mechanisms of Cancer-Induced Bone Pain. / Falk, Sarah; Dickenson, Anthony H.

In: Journal of Clinical Oncology, Vol. 32, No. 16, 05.05.2014, p. 1647-1654.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Falk, S & Dickenson, AH 2014, 'Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain', Journal of Clinical Oncology, vol. 32, no. 16, pp. 1647-1654. https://doi.org/10.1200/JCO.2013.51.7219

APA

Falk, S., & Dickenson, A. H. (2014). Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain. Journal of Clinical Oncology, 32(16), 1647-1654. https://doi.org/10.1200/JCO.2013.51.7219

Vancouver

Falk S, Dickenson AH. Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain. Journal of Clinical Oncology. 2014 May 5;32(16):1647-1654. https://doi.org/10.1200/JCO.2013.51.7219

Author

Falk, Sarah ; Dickenson, Anthony H. / Pain and Nociception : Mechanisms of Cancer-Induced Bone Pain. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 16. pp. 1647-1654.

Bibtex

@article{417ecac04e6d439d842fd3336e7b974e,
title = "Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain",
abstract = "Cancer pain, especially pain caused by metastasis to bone, is a severe type of pain, and unless the cause and consequences can be resolved, the pain will become chronic. As detection and survival among patients with cancer have improved, pain has become an increasing challenge, because traditional therapies are often only partially effective. Until recently, knowledge of cancer pain mechanisms was poor compared with understanding of neuropathic and inflammatory pain states. We now view cancer-induced bone pain as a complex pain state involving components of both inflammatory and neuropathic pain but also exhibiting elements that seem unique to cancer pain. In addition, the pain state is often unpredictable, and the intensity of the pain is highly variable, making it difficult to manage. The establishment of translational animal models has started to reveal some of the molecular components involved in cancer pain. We present the essential pharmacologic and neurobiologic mechanisms involved in the generation and continuance of cancer-induced bone pain and discuss these in the context of understanding and treating patients. We discuss changes in peripheral signaling in the area of tumor growth, examine spinal cord mechanisms of sensitization, and finally address central processing. Our aim is to provide a mechanistic background for the sensory characteristics of cancer-induced bone pain as a basis for better understanding and treating this condition.",
author = "Sarah Falk and Dickenson, {Anthony H}",
year = "2014",
month = may,
day = "5",
doi = "10.1200/JCO.2013.51.7219",
language = "English",
volume = "32",
pages = "1647--1654",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

RIS

TY - JOUR

T1 - Pain and Nociception

T2 - Mechanisms of Cancer-Induced Bone Pain

AU - Falk, Sarah

AU - Dickenson, Anthony H

PY - 2014/5/5

Y1 - 2014/5/5

N2 - Cancer pain, especially pain caused by metastasis to bone, is a severe type of pain, and unless the cause and consequences can be resolved, the pain will become chronic. As detection and survival among patients with cancer have improved, pain has become an increasing challenge, because traditional therapies are often only partially effective. Until recently, knowledge of cancer pain mechanisms was poor compared with understanding of neuropathic and inflammatory pain states. We now view cancer-induced bone pain as a complex pain state involving components of both inflammatory and neuropathic pain but also exhibiting elements that seem unique to cancer pain. In addition, the pain state is often unpredictable, and the intensity of the pain is highly variable, making it difficult to manage. The establishment of translational animal models has started to reveal some of the molecular components involved in cancer pain. We present the essential pharmacologic and neurobiologic mechanisms involved in the generation and continuance of cancer-induced bone pain and discuss these in the context of understanding and treating patients. We discuss changes in peripheral signaling in the area of tumor growth, examine spinal cord mechanisms of sensitization, and finally address central processing. Our aim is to provide a mechanistic background for the sensory characteristics of cancer-induced bone pain as a basis for better understanding and treating this condition.

AB - Cancer pain, especially pain caused by metastasis to bone, is a severe type of pain, and unless the cause and consequences can be resolved, the pain will become chronic. As detection and survival among patients with cancer have improved, pain has become an increasing challenge, because traditional therapies are often only partially effective. Until recently, knowledge of cancer pain mechanisms was poor compared with understanding of neuropathic and inflammatory pain states. We now view cancer-induced bone pain as a complex pain state involving components of both inflammatory and neuropathic pain but also exhibiting elements that seem unique to cancer pain. In addition, the pain state is often unpredictable, and the intensity of the pain is highly variable, making it difficult to manage. The establishment of translational animal models has started to reveal some of the molecular components involved in cancer pain. We present the essential pharmacologic and neurobiologic mechanisms involved in the generation and continuance of cancer-induced bone pain and discuss these in the context of understanding and treating patients. We discuss changes in peripheral signaling in the area of tumor growth, examine spinal cord mechanisms of sensitization, and finally address central processing. Our aim is to provide a mechanistic background for the sensory characteristics of cancer-induced bone pain as a basis for better understanding and treating this condition.

U2 - 10.1200/JCO.2013.51.7219

DO - 10.1200/JCO.2013.51.7219

M3 - Review

C2 - 24799469

VL - 32

SP - 1647

EP - 1654

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -

ID: 111188562